Foventa Therapeutics Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
17
- Latest Deal Type
-
Series A
- (Upcoming)
- Investors
-
11
Foventa Therapeutics General Information
Description
Developer of a biopharmaceutical drug designed to improve the treatment of patients with retinal vascular diseases and to improve the lives of those suffering from vision loss. The company offers program molecules for wet age-related macular degeneration, which act via a novel mechanism of action to inhibit pathological blood vessels and reduce the formation of pathological vascular endothelial growth factor without inhibiting beneficial, non-pathological vascular endothelial growth factor (VEGF), enabling the healthcare industry to focus on developing therapies for wet age-related macular degeneration.
Contact Information
Website
www.foventa.comCorporate Office
- WTL Moorfield Road, Duxford
- Cambridgeshire
- Cambridge CB22 4PS
- England, United Kingdom
Corporate Office
- WTL Moorfield Road, Duxford
- Cambridgeshire
- Cambridge CB22 4PS
- England, United Kingdom
Foventa Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC (Series A) | Upcoming | Clinical Trials - Phase 2 | ||||
| 8. Secondary Transaction - Private | 01-Jul-2026 | Completed | Clinical Trials - Phase 2 | |||
| 7. Later Stage VC (Series A) | 03-Jan-2019 | Completed | Clinical Trials - Phase 2 | |||
| 6. Later Stage VC | 12-Sep-2018 | Completed | Clinical Trials - Phase 1 | |||
| 5. Grant | 06-Feb-2017 | Completed | Clinical Trials - Phase 1 | |||
| 4. Early Stage VC | 01-Dec-2016 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC | 05-Oct-2015 | Completed | Clinical Trials - Phase 1 | |||
| 2. Seed Round | 01-Mar-2014 | $651K | $651K | Completed | Clinical Trials - Phase 1 | |
| 1. University Spin-Out | 01-Jan-2013 | Completed | Startup |
Foventa Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 14,141 | $0.012877 | $72.11 | $72.11 | 1x | $72.11 | 17.79% | |
| Ordinary | 7,860 | $0.012877 | $64.39 | $64.39 | 1x | $64.39 | 9.89% |
Foventa Therapeutics Comparisons
Industry
Financing
Details
Foventa Therapeutics Competitors (28)
One of Foventa Therapeutics’s 28 competitors is TearSolutions, a Venture Capital-Backed company based in Charlottesville, VA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| TearSolutions | Venture Capital-Backed | Charlottesville, VA | ||||
| Allegro Ophthalmics | Venture Capital-Backed | San Juan Capistrano, CA | ||||
| EyePoint | Corporation | Watertown, MA | ||||
| Apellis Pharmaceuticals | Formerly VC-backed | Waltham, MA | ||||
| Kala Bio | Formerly VC-backed | Arlington, MA |
Foventa Therapeutics Patents
Foventa Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021309894-A1 | 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases | Active | 14-Jul-2020 | ||
| AU-2021309894-B2 | 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases | Active | 14-Jul-2020 | ||
| CA-3183466-A1 | 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases | Pending | 14-Jul-2020 | ||
| EP-4182311-A1 | 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases | Active | 14-Jul-2020 | ||
| EP-4182311-B1 | 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases | Active | 14-Jul-2020 | C07D405/14 |
Foventa Therapeutics Signals
Foventa Therapeutics Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| EMV Capital | Venture Capital | Minority | ||
| Stoic Venture Capital | Venture Capital | Minority | ||
| University of Bristol Endowment | Limited Partner | Minority | ||
| R42 Group | Venture Capital | Minority | ||
| Martlet Capital | Venture Capital | Minority |
Foventa Therapeutics FAQs
-
When was Foventa Therapeutics founded?
Foventa Therapeutics was founded in 2013.
-
Where is Foventa Therapeutics headquartered?
Foventa Therapeutics is headquartered in Cambridge, United Kingdom.
-
What is the size of Foventa Therapeutics?
Foventa Therapeutics has 17 total employees.
-
What industry is Foventa Therapeutics in?
Foventa Therapeutics’s primary industry is Drug Discovery.
-
Is Foventa Therapeutics a private or public company?
Foventa Therapeutics is a Private company.
-
What is Foventa Therapeutics’s current revenue?
The current revenue for Foventa Therapeutics is .
-
How much funding has Foventa Therapeutics raised over time?
Foventa Therapeutics has raised $7.74M.
-
Who are Foventa Therapeutics’s investors?
EMV Capital, Stoic Venture Capital, University of Bristol Endowment, R42 Group, and Martlet Capital are 5 of 11 investors who have invested in Foventa Therapeutics.
-
Who are Foventa Therapeutics’s competitors?
TearSolutions, Allegro Ophthalmics, EyePoint, Apellis Pharmaceuticals, and Kala Bio are some of the 28 competitors of Foventa Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process